We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

COPAN ITALIA SPA

Copan is dedicated to developing high-quality sample collection products for infectious diseases, human genomics, env... read more Featured Products: More products

Download Mobile App




AST Automation System Rapidly Diagnoses Blood Stream Infection for Early Treatment Initiation

By LabMedica International staff writers
Posted on 12 May 2022

Every year, 30 million people worldwide get affected by a blood stream infection, pathologies often caused by antibiotic-resistant bacteria and characterized by up to 30% mortality. More...

In these patients, reducing the time to diagnosis is not simply a good service, as the rapidity of appropriate treatment initiation may decrease their short-term mortality. Thus, any slight improvement in the complex and multitasked workflow that interposes between a blood sample collection and diagnosis can be life-saving. Now, a new antimicrobial susceptibility testing (AST) automation system guarantees the shortest four hours incubation time for positive blood culture samples, thereby reducing the incubation time for blood stream infection patients to allow for early intervention with a targeted antimicrobial therapy.

Copan Group’s (Brescia, Italy) Radian is an integrated module of the company’s full lab automation ecosystem that already eases the AST tasks of healthcare professionals by automating antibiotic disks application on WASPLab streaked plates, followed by automated incubation, digital imaging, and interpretation to derive antibiotic susceptibility results. Disk diffusion is the only antibiotic susceptibility testing that provides a true image of bacterial growth, enabling microbiologists to detect culture purity, heterogeneous growth or colony morphology, as well as antibiotic interactions, to adapt antimicrobial treatment more rapidly.​ With Radian, automation gets rid of the disadvantages linked to manual disk diffusion while maintaining at the same time its original advantages.

Copan has now pushed Radian even further to develop Radian BC. Integrating EUCAST Rapid AST Rules (R-AST) into the automated workflow, Radian BC is the first platform to provide accurate therapy indications for blood stream infection patients with just a four hour incubation period. Like no other AST automation available today, Radian BC guarantees the shortest four hours incubation time for positive blood culture samples. By reducing the incubation time for blood stream infection patients to a quarter, Radian BC ensures to specialists unparalleled rapid diagnostic assessment, directing each patient towards an early intervention with a targeted antimicrobial therapy.

Related Links:
Copan Group 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gastrointestinal Panel
Xpert® GI Panel
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.